Cardiac Resynchronization Therapy Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End-use (Hospitals, Cardiac Centers, Others), By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The global cardiac resynchronization therapy market size was exhibited at USD 4.28 billion in 2023 and is projected to hit around USD 6.91 billion by 2033, growing at a CAGR of 4.9% during the forecast period of of 2024 to 2033.

Key Takeaways:

• North America held more than 51.0% share of the cardiac resynchronization therapy market in 2023. 
• CRT-Defibrillators accounted for more than 75.0% share of the cardiac resynchronization therapy market by product in 2023.
• By end-user, hospitals held the largest share of about 52.08% of the cardiac resynchronization therapy market in 2023.

Cardiac Resynchronization Therapy Market Report Scope

Growing product developments, an aging population, initiatives by key companies, and the prevalence of cardiovascular diseases are some of the key drivers of this market. Boston Scientific, for instance, reported cumulative distribution of around 389,000 CRT-Ds globally as of January 2023. During 2023, the company sold around 33,000 CRT-Ds; out of which, about 16,500 were registered in the U.S., which is indicative of high demand.

The COVID-19 pandemic adversely impacted the cardiac resynchronization therapy market with dampened demand and sales. This was due to pandemic-induced deferred or canceled elective procedures, delays in clinical trials, supply chain challenges, and reduced sales and marketing activities. Several key companies such as Medtronic, Boston Scientific, and Microport reported a negative impact of COVID-19 on their financial performance and business activities. For instance, Microport reported a 16.2% decline in its cardiac rhythm management business in 2023. The company attributed the decline to postponed outpatient visits and surgical procedures due to COVID-19, thus resulting in a decreased number of implants.

After the initial shock and confusion about COVID-19 effects, companies and governments began taking corrective actions to help the economy and businesses recover. These initiatives included lowering conditional exemptions, limitations, and other tactical steps, in addition to policy and monetary support. In April 2023, COVID-19 task force update, the Heart Rhythm Society released guidelines for managing patients with cardiac implantable electronic devices with an emphasis on limiting exposure to patients and providers. It indicated that only major issues involving device leads, generators, or reprogramming need in-person visits. This was used by Biotronik to promote its line of implanted devices for cardiac rhythm management that feature home monitoring technology for continuity of care. Following the peak of COVID-19, the American College of Cardiology (ACC), the Canadian Association of Interventional Cardiology (CAIC), and other North American cardiology organizations presented suggestions for ethically and safely resuming invasive cardiovascular procedures. The market for CRT devices was aided by these regulations. 

The aging population is a key factor estimated to fuel market growth. Statistics Korea estimated that about 8.53 million individuals are aged 65 years and older in 2023. This number is expected to reach 12.98 million by 2030. The aging population indicates a growing number of people at risk of chronic diseases, such as congestive heart failure, hypertension, and arrhythmia. This is anticipated to contribute to market growth in the country. According to a survey conducted by the European Society of Cardiology and published in the Archives of Cardiovascular Diseases in 2019, French patients were found to be more likely to receive a CRT-P implant compared to the rest of Europe. The patients were identified to be comparatively older, with about 44.7% aged 75 years and above, had fewer co-morbidities, and less severe heart failure symptoms.

Rising product improvements, R&D initiatives by market players, and the prevalence of cardiovascular diseases are expected to fuel market growth. For instance, in February 2023, Abbott received CE Marking for its Gallant ICDs and CRT-D devices. These technologies enhance the company's solutions by enabling remote monitoring through Abbott's myMerlinPuls App. MultiPoint Pacing and SyncAV feature further enhance the Gallant CRT-D system to improve patient response to CRT therapy. This supported the company’s growth objectives. The Spanish Pacemaker Registry reported that, in 2023, about 3,850 CRT devices were implanted in Spain. Out of the implanted devices, 2,387 were CRT-D devices and 1,463 were CRT-P devices. It was reported that recipients were 78.8 years old on average. Syncope was found to be the symptom that led to implantation in 41.8% of cases. Dizziness and heart failure were found to be the other symptoms. 

Segments Insights:

Product Insights

CRT-Defibrillators accounted for more than 75.0% share of the cardiac resynchronization therapy market by product in 2023. The CRT-P segment, on the other hand, is expected to expand at the fastest CAGR of over 6.0% during the forecast period. This is owing to include increasing geriatric population across the globe, the prevalence of cardiac conditions, and product advancements by key market players. Additionally, more doctors continue to suggest CRT-P usage for heart failure patients who would benefit more from pacing than defibrillation, resulting in driving the CRT-P to expand at the fastest CAGR during the forecast period.

Using information from the Japan Cardiac Device Treatment Registry, a study from 2023 was published in the Journal of Arrhythmia (JCDTR). In patients aged 75 years and older in Japan, the research showed an upward trend in the percentage of ICDs, CRT-Ds, and CRT-Ps implanted for the first time. Over a decade, researchers counted 17,564, 9,470, and 1,087 patients that had ICD implants, CRT-D implants, and CRT-P implants, respectively. 

End-use Insights

By end-user, hospitals held the largest share of about 52.08% of the cardiac resynchronization therapy market in 2023. This is attributable to the high consumption of CRT devices in hospitals as most surgeries are performed in hospital settings. For instance, the UAE's Aster Hospital reported a 61-year-old man with significant heart failure who experienced regular episodes of fast and life-threatening heartbeats having CRT-D implanted.

The Cardiac Center segment is anticipated to register the fastest growth of 5.1% due to the increasing number of cardiac specialty centers and the prevalence of cardiovascular diseases. According to CDC, as of September 2023, around 6.2 million adults in the U.S. suffered from heart failure. Furthermore, according to the American College of Cardiology Foundation, the prevalence of cardiovascular diseases rose from 271 million to 523 million from 1990 to 2019. 

Regional Insights

North America held more than 51.0% share of the cardiac resynchronization therapy market in 2023. The large share of the North American region is its increasing geriatric population and growing regulatory approvals. Physical inactivity due to a sedentary lifestyle can increase the risk of developing chronic cardiac conditions, which may propel the need for cardiovascular care.

Asia Pacific is projected to expand at the fastest CAGR of 6.3% over the next few years. This is owing to developing healthcare infrastructure, an aging population, improvement in economic conditions, strategic initiatives by key companies, and the growing prevalence of cardiac diseases. For example, MicroPort is a Chinese company specializing in a variety of medical devices, including CRT-Ds and CRT-Ps. The company is a domestic leader in the cardiac rhythm management market. It registered a 95% year-on-year growth in revenue during H1 2023 (with a revenue of about USD 6 million) in China, owing to a wide portfolio and robust product pipeline. This growth was driven by cost-effectiveness and brand recognition, facilitating the company to cover 584 hospitals across the country. 

Some of the prominent players in the Cardiac resynchronization therapy market include:

• Medtronic
• Abbott
• Boston Scientific Corporation
• Biotronik SE & Co., KG
• MicroPort Scientific Corporation
• Livanova plc.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2023 to 2033. For this study, Nova one advisor, Inc. has segmented the global cardiac resynchronization therapy market.

Product

• CRT-Defibrillator
• CRT-Pacemaker

End-use

• Hospital
• Cardiac Center
• Others

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)